Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paraspinous Bupivacaine Injections vs Prochlorperazine for Benign Headache
NCT01785459Phase 2
Key facts
- Status
- Terminated
- Start
- Oct 2013
- Primary completion
- Jul 2016
- Countries
- 1
- Sponsor
- Wake Forest University Health Sciences
- Modality
- Small Molecules
- Conditions
- Headache
01
Overview
Phase 2, randomised, open-label trial of bupivacaine hydrochloride 0.75% injection in Headache (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Length of Stay and Incidence of Immediate and Post-discharge Complications at 72 hours. Started Oct 2013; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
Standard Care
IV Prochlorperazine
Treatment
0.5% Bupivacaine Injection
03
Endpoints
Primary
Length of Stay
Incidence of Immediate and Post-discharge Complications
Secondary
Symptomatic Relief of Headache
Beyond the preview
Go deeper on NCT01785459.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01785459.